Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models
Science Translational Medicine · 16.07.2025 · 17 (807)
DOI: 10.1126/scitranslmed.adv0766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 16.07.2025. Verfasst von Qianling Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, Sixth Affiliated Hospital of Su…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Sirtuin 2, MutL Protein Homolog 1, Immunity. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Low tumor mutation burden and an immunosuppressive tumor microenvironment (TME) of colorectal cancers (CRCs) contribute to resistance to immune-checkpoint inhibitors in patients. Understanding the mechanisms of cancer immune evasion will be helpful to develop new therapeutic strategies. Here, leveraging mass spectrometry–based proteomic profiling data and clinical validation, we identified that low sirtuin 2 (SIRT2) expression was associated with improved prognosis and an immune-active TME in CRC. Specifically, genetic knockdown or pharmacological inhibition of SIRT2 resulted in enhanced infiltration and cytotoxicity of CD8 + T cells, leading to tumor regression across multiple CRC mouse models and patient-derived organoids. Further in vitro experimental analysis demonstrated that SIRT2 interacted with and deacetylated MutL protein homolog 1 (MLH1) at Lys 402/443/461 , thereby preventing MLH1 ubiquitination and degradation. SIRT2 knockdown or inhibition down-regulated MLH1, increasing DNA damage and activating the cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) pathway. In addition, both in vivo and in vitro experiments indicated that SIRT2 inhibition stimulated the production of tumor neoantigens and enhanced major histocompatibility complex class I (MHC-I) expression, reprogramming the TME toward an immune-active status and inducing long-lasting immune memory. Last, a combination strategy using SIRT2 inhibitor 2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide (AGK2) and anti–programmed cell death protein–1 (PD-1) therapy enhanced immune response, making tumors susceptible to immunotherapy and driving substantial tumor regression in vivo. Our study uncovers a role of SIRT2 in reprogramming TME and underscores the potential of targeting SIRT2 to sensitize CRC to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
- Biomedical Innovation Center, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
- Department of General Surgery (Colorectal Surgery), Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
- Department of Clinical Laboratory, Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
ORCID-Profile: Qianling Gao, Lanlan Yang, Shubiao Ye, Mingru Mai, Yiting Liu, Xuefei Jiang, Xingzhi Feng, Zihuan Yang
Zitieren
APA
Gao, Q., Yang, L., Ye, S., Mai, M., Liu, Y., Jiang, X., Feng, X., & Yang, Z. (2025). Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models. Science Translational Medicine, 17(807). https://doi.org/10.1126/scitranslmed.adv0766
Vancouver
Gao Q, Yang L, Ye S, Mai M, Liu Y, Jiang X, et al. Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models. Science Translational Medicine. 2025;17(807). doi:10.1126/scitranslmed.adv0766
BibTeX
@article{Gao2025,
author = {Gao, Qianling and Yang, Lanlan and Ye, Shubiao and Mai, Mingru and Liu, Yiting and Jiang, Xuefei and Feng, Xingzhi and Yang, Zihuan},
title = {Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {807},
doi = {10.1126/scitranslmed.adv0766}
}
EUVIMED